SCHEMBL26263236

SCHEMBL26263236

CC[C@H](NC(=O)c1ccc(-c2ccccc2OC)o1)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.60
KDM4E B2RXH2 5/20 0.60
HPGD P15428 4/20 0.60
HSD17B10 Q99714 2/20 0.60
TDP1 Q9NUW8 2/20 0.60
MAPT P10636 4/20 0.54
RAB9A P51151 4/20 0.54
NPC1 O15118 3/20 0.54
SLC9A1 P19634 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 2/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 1/20 0.49
TSHR P16473 1/20 0.49
ATM Q13315 1/20 0.49
SUCNR1 Q9BXA5 1/20 0.48
MME P08473 1/20 0.46
ITGB1 P05556 3/20 0.45
ITGA4 P13612 3/20 0.45
ITGB7 P26010 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26264361 0.89 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL12071450 0.85 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL26263212 0.85 ALDH1A1 (0.62) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL26263209 0.83 SUCNR1 (0.61) ALDH1A1HPGDSUCNR1
SCHEMBL26263243 0.78 SUCNR1 (0.68) ALDH1A1MAPTSUCNR1
SCHEMBL9756269 0.77 HPGD (0.61) ALDH1A1HPGDMAPTRAB9ANPC1
SCHEMBL26263201 0.77 SUCNR1 (0.60) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL5842967 0.76 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL26263232 0.75 SUCNR1 (0.61) SUCNR1
SCHEMBL26263219 0.75 SUCNR1 (0.61) ALDH1A1KDM4EHPGDSUCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293504-A1 TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION UNIV NEW YORK (US) 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293504-A1 TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION SUCNR1, SYNGR2, TSPO ALDH1A1 1666/4885KDM4E 3613/4885HPGD 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.